Abstract
BackgroundMedical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum. We evaluated changes in survival rates for this cancer following these advances by analyzing data from population-based cancer registries in Japan.MethodsData were available for 8562 cases of cancer of the corpus uteri from six prefectural cancer registries. We defined the two periods of 1993–2000 (1st period) and 2001–2006 (2nd period). Relative survival (RS) in each period was calculated to assess changes using an excess mortality model, with adjustment for age group (15–54, 55–69, and 70–99 years), extent of disease (localized, regional, and distant), and histological subtype.ResultsOverall 5-year RS improved from 77.7% in the 1st period to 80.2% in the 2nd period, with an excess hazard ratio (EHR) of 0.785 (95% confidence interval [CI], 0.705–0.873). Five-year RS significantly improved in the group aged 55–69 years, in all groups by extent of disease, and in the endometrioid adenocarcinoma group. In particular, 5-year RS significantly improved in patients with endometrioid adenocarcinoma, from 84.5% to 89.7%, with an EHR of 0.698 (95% CI, 0.560–0.870).ConclusionOverall 5-year RS for cancer of the corpus uteri in Japan improved from the 1990s to early 2000s. These improvements might have been aided by the comprehensive medical development of management for this cancer, including the spread of concomitant therapy with taxane and platinum as a standard adjuvant chemotherapy in the early 2000s.
Highlights
Treatment for cancer of the corpus uteri changed from the late 1990s to early 2000s with the introduction of concomitant therapy with taxane and platinum
The Surveillance, Epidemiology, and End Results Program (SEER) in the United States reported a 5-year relative survival (RS) for this cancer of 83.3% from 2005 to 2011,1 while a European Cancer Registry-based study reported a rate of 76.2% from 2000 to 2007.2 In Japan, 5-year RS using subjects registered with a Japanese population-based registry was 79.8% between 2003 and 2005.3 Cancer of the corpus uteri is generally recognized as having a favorable prognosis because most patients are diagnosed at an early stage.[4]
The proportion of patients aged 70 years or older and those with endometrioid adenocarcinoma increased from the 1st to the 2nd period, whereas proportions of the extent of disease did not differ between the two periods
Summary
Treatment for cancer of the corpus uteri changed from the late 1990s to early 2000s with the introduction of concomitant therapy with taxane and platinum. Population-based studies of survival trends for this cancer have been reported in Japan and other developed countries, no study has detailed changes following improvements in treatment, including the introduction of concomitant therapy with taxane and platinum. Medical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
